– USA, MD – REGENXBIO Inc. (NASDAQ:RGNX), a leading biotechnology company focused on the development, commercialization and licensing of recombinant adeno-associated virus gene therapy based on its proprietary NAV Technology Platform, today announced the appointment of Daniel J. Abdun-Nabi to its board of directors, effective as of August 5, 2016.
“Dan is an experienced biopharmaceutical leader who brings to REGENXBIO more than 25 years of success in key strategic, operational, legal and board roles,” said Don Hayden, Chairman of REGENXBIO’s board of directors. “We are excited to have Dan join the board at this important point in the growth and development of the company.”
Mr. Abdun-Nabi has served as President and Chief Executive Officer of Emergent BioSolutions Inc. since April 2012. Since joining Emergent in 2004, he has held several senior leadership positions including Chief Operating Officer and General Counsel. Prior to joining Emergent, Mr. Abdun-Nabi served as General Counsel for IGEN International, Inc., and as Senior Vice President – Legal Affairs, General Counsel and Secretary at North American Vaccine, Inc. Mr. Abdun-Nabi received a Master of Laws in taxation from Georgetown University Law Center, a J.D. from the University of San Diego School of Law and a B.A. in political science from the University of Massachusetts, Amherst.
“REGENXBIO’s proprietary NAV Technology Platform has ushered in a new era of gene therapy innovation with the potential to transform the lives of patients suffering from serious diseases with unmet needs,” said Mr. Abdun-Nabi. “I look forward to contributing to REGENXBIO’s continued success as the company advances its gene therapy treatments into clinical development.”
In addition, REGENXBIO announced that Camille Samuels resigned from its board of directors on August 5, 2016. “I would like to recognize and thank Camille for her sound guidance and many contributions as an early investor in REGENXBIO,” said Kenneth T. Mills, President and Chief Executive Officer of REGENXBIO. “Camille played an instrumental role in the growth of the company and recognized the opportunity for our NAV Technology Platform to improve the lives of patients.”
REGENXBIO is a leading biotechnology company focused on the development, commercialization and licensing of recombinant adeno-associated virus (AAV) gene therapy. REGENXBIO’s NAV® Technology Platform, a proprietary AAV gene delivery platform, consists of exclusive rights to more than 100 novel AAV vectors, including AAV7, AAV8, AAV9 and AAVrh10. REGENXBIO’s mission is to transform the lives of patients suffering from severe diseases with significant unmet medical need by developing and commercializing in vivo gene therapy products based on REGENXBIO’s NAV Technology Platform. REGENXBIO seeks to accomplish this mission through a combination of internal development efforts and third-party NAV Technology Platform licensees. As of March 31, 2016, REGENXBIO’s NAV Technology Platform was being applied in the development of 28 product candidates for a variety of diseases, including five internally developed candidates and 23 partnered candidates developed by REGENXBIO’s licensees.
- Disclaimer - News, data, and statements included in this release are intended exclusively for general information purposes. Talent4Boards does not guarantee that news is accurate or about the correct person and accepts neither liability for the consequences of the reader’s reliance, nor responsibility for the accuracy of the information. Nothing in this release should be considered for decisions about referred securities. Products and brand names may be trademarks or registered trademarks of their respective owners.